THE YB-1 COMPANY
DEAD

Serial Number

78977507

Owner

XVir Therapeutics GmbH

Attorney

Matthew J. Smith

Filing Date

Mar 21, 2005

Add to watchlist:

No watchlists yet
View on USPTO

THE YB-1 COMPANY Trademark

Serial Number: 78977507 • Registration: 3423030

THE YB-1 COMPANY is a trademark filed by XVir Therapeutics GmbH on March 21, 2005. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

XVir Therapeutics GmbH (5 trademarks)

Nymphenburger Str. 1
Munich D080335 , DE

Entity Type: 16

Trademark Details

Filing Date

March 21, 2005

Registration Date

May 6, 2008

Published for Opposition

January 2, 2007

Cancellation Date

December 12, 2014

Goods & Services

Scientific laboratory equipment, namely, photometers, mass spectrometers, ELISA readers, positron emission tomography (PET) scanners, thermocyclers, nuclear magnetic resonance (NMR) spectrometers, fluorescence-activated cell sorters, cell counters, blotting devices using electric, magnetic or capillary forces for material transfer

Pharmaceutical and veterinary preparations, namely chemical products for medical and veterinary clinical use, namely nucleic acids, vectors, plasmids, viruses, peptides and proteins, lipids, lipid coated proteins, lipid coated nucleic acids, lipid coated viruses, lipid coated vectors, lipid coated plasmids, antibodies, anticalines, aptamers, aptamers consisting essentially of L-nucleotides, short limiting RNA molecules without specific limitation to the number of nucleotides, antisense oligonucleotides, ribosomes, decoy oligonucleotides; slimming agents, appetite suppressants, acidosis therapeutics, analeptics, antihypoximics, analgesics, antirheumatic drugs, antihelmintics, antiallergics, anti-anemia drugs, antiarrhythmics, antibiotics, anti-infective agents, antidementics, nootropics, antidiabetics, antidotes, antiemetics, antivertiginosics, antiepileptics, antihemorrhagics, antifibrinolytics, hemostatics, antihypertonics, antihypoglycemics, antihypotonics, anticoagulants, antimycotics, antiparasitic agents, antiphlogistics, expectorants, agents for use in atherosclerosis, balneotherapeutics and preparations for heat therapy, beta receptor blocking agents, calcium channel blocking agents and inhibitors of the renin-angiotensin-system, broncholytics, antiasthmetics, cholagoguegics and biliary tract therapeutics, cholinergics, corticoids, dermatics, general purpose disinfectants, antiseptics, dietetic foods adapted for medical use, alimentary therapeutics, diagnostic preparations for medical and veterinary use, diuretics, preparations for the stimulation of blood circulation, fibrinolytics, geriatric agents for the treatment of stress and age-related diseases, geriatric nutritional supplements, agents for use in gout, agents for use in flu and in catarrhal fever, gynecological agents, hemorrhoid agents, hepatics, hypnotics, sedatives, cardiac therapeutics, agents for removal of dental stain, agents for reconstitution of gums, materials for dental fillings and for dental sealing purposes, corona agents, laxatives, antilipaemics, local anesthetics, neural therapeutics, gastro-intestinal agents, migraine agents, mineral supplements, mouth and pharyngeal therapeutics, muscle relaxants, narcotics, neuropathical agents and other neurotropic agents, ophthalmic preparations, agents for use in osteoporosis, calcium metabolism modifying agents, agents for use in Parkinson's Disease and other agents against disturbances of the extrapyramidal system, psychotropic agents, rhinologics, sinositic agents, roborants, thyroidal therapeutics, spasmolytics, inhibitors of thrombocyte aggregation, tuberculosis agents, altemants, urologics, venous agents, vitamins, cytostatics and other antineoplastic agents and protectives, homeopathic supplements; and Pharmaceutical and veterinary preparations in the nature of viruses, viruses for oncolysis, viruses for gene therapy, viruses for delivery of pharmaceutically active compounds, viruses for restoration of drug sensitivity, viruses for restoration of apoptosis, and viruses for cancer therapy, all for clinical use

Chemical products for research use and for use in the manufacture of pharmaceuticals, namely nucleic acids, vectors, plasmids, viruses, peptides and proteins, lipids, lipid coated proteins, lipid coated nucleic acids, lipid coated viruses, lipid coated vectors, lipid coated plasmids, antibodies, anticalines, aptamers, aptamers consisting essentially of L-nucleotides, short limiting RNA molecules without specific limitation to the number of nucleotides, antisense oligonucleotides, ribozymes, decoy oligonucleotides

Medical services featuring physicians and surgeons; veterinary services; medical services, namely, determination of individual disease risk, determination of individual cancer therapy, identifying patient groups treatable by oncolytic viruses, individual health care and managed health care services

Scientific and medical research services in biology, molecular biology, chemistry, biochemistry, genetics, molecular genetics, and pathology; scientific and medical research services for third parties, namely, determination of viral particles, determination and sequencing of viral genome, determination of drug resistance in samples, determination of radiation resistance in samples, design of viral vectors, design of plasmid vectors, design of viruses and in particular oncolytic viruses; scientific and medical research services, namely, design and performance of clinical trials

Filing History

CANCELLED SEC. 8 (6-YR)
Dec 12, 2014 C8..
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 22, 2011 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 3, 2010 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 3, 2010 REAP
REGISTERED-PRINCIPAL REGISTER
May 6, 2008 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Apr 2, 2008 DP1B
NOTICE OF ALLOWANCE CANCELLED
Mar 27, 2008 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Mar 27, 2008 D1BR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 15, 2007 CHAN
PAPER RECEIVED
Oct 25, 2007 MAIL
SOU EXTENSION 1 GRANTED
Sep 25, 2007 EX1G
SOU EXTENSION 1 FILED
Sep 25, 2007 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 25, 2007 EEXT
NOA MAILED - SOU REQUIRED FROM APPLICANT
Mar 27, 2007 NOAM
PUBLISHED FOR OPPOSITION
Jan 2, 2007 PUBO
NOTICE OF PUBLICATION
Dec 13, 2006 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Nov 9, 2006 PREV
ASSIGNED TO LIE
Nov 8, 2006 ALIE
ASSIGNED TO LIE
Oct 5, 2006 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 28, 2006 CNSA
DIVISIONAL PROCESSING COMPLETE
Aug 25, 2006 DPCC
DIVISIONAL REQUEST RECEIVED
Aug 10, 2006 DRRR
PAPER RECEIVED
Aug 10, 2006 MAIL
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Aug 8, 2006 GEAP
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Aug 8, 2006 CPEA
ALLOWANCE WITHDRAWN-INADVERTENTLY ISSUED ACTION
Jul 21, 2006 ZZBX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Jul 10, 2006 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 15, 2006 PREV
ASSIGNED TO LIE
Jun 14, 2006 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 5, 2006 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 1, 2006 XAEC
EXAMINERS AMENDMENT E-MAILED
Jun 1, 2006 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 1, 2006 CNEA
AMENDMENT FROM APPLICANT ENTERED
May 9, 2006 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 18, 2006 CRFA
PAPER RECEIVED
Apr 18, 2006 MAIL
NON-FINAL ACTION E-MAILED
Dec 2, 2005 GNRT
NON-FINAL ACTION WRITTEN
Dec 2, 2005 CNRT
AMENDMENT FROM APPLICANT ENTERED
Nov 4, 2005 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 21, 2005 CRFA
PAPER RECEIVED
Oct 21, 2005 MAIL
CORRESPONDENCE E-MAILED
Oct 19, 2005 GRML
NON-FINAL ACTION WRITTEN
Oct 19, 2005 CNRT
ASSIGNED TO EXAMINER
Oct 13, 2005 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Mar 30, 2005 AMPX
TEAS VOLUNTARY AMENDMENT RECEIVED
Mar 30, 2005 PARI
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 30, 2005 TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 30, 2005 TCCA
NEW APPLICATION ENTERED
Mar 28, 2005 NWAP